CN120514709A - 用于治疗癌症的menin-mll抑制剂 - Google Patents

用于治疗癌症的menin-mll抑制剂

Info

Publication number
CN120514709A
CN120514709A CN202510715666.3A CN202510715666A CN120514709A CN 120514709 A CN120514709 A CN 120514709A CN 202510715666 A CN202510715666 A CN 202510715666A CN 120514709 A CN120514709 A CN 120514709A
Authority
CN
China
Prior art keywords
compound
subject
inhibitor
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510715666.3A
Other languages
English (en)
Chinese (zh)
Inventor
布里格斯·W·莫里森
杰拉德·M·麦吉汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndax Pharmaceuticals Inc
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of CN120514709A publication Critical patent/CN120514709A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202510715666.3A 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂 Pending CN120514709A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263339635P 2022-05-09 2022-05-09
US63/339,635 2022-05-09
PCT/US2023/021604 WO2023220098A1 (en) 2022-05-09 2023-05-09 Menin-mll inhibitors for the treatment of cancer
CN202380049030.9A CN119403557A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202380049030.9A Division CN119403557A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂

Publications (1)

Publication Number Publication Date
CN120514709A true CN120514709A (zh) 2025-08-22

Family

ID=88730925

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202510715666.3A Pending CN120514709A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂
CN202510715560.3A Pending CN120531737A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂
CN202380049030.9A Pending CN119403557A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510715560.3A Pending CN120531737A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂
CN202380049030.9A Pending CN119403557A (zh) 2022-05-09 2023-05-09 用于治疗癌症的menin-mll抑制剂

Country Status (10)

Country Link
US (1) US20250295661A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522174A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516558A (cg-RX-API-DMAC7.html)
KR (1) KR20250020447A (cg-RX-API-DMAC7.html)
CN (3) CN120514709A (cg-RX-API-DMAC7.html)
AU (1) AU2023269033A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252288A1 (cg-RX-API-DMAC7.html)
IL (1) IL316829A (cg-RX-API-DMAC7.html)
MX (1) MX2024013787A (cg-RX-API-DMAC7.html)
WO (1) WO2023220098A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
AR125866A1 (es) * 2021-05-14 2023-08-23 Syndax Pharmaceuticals Inc Inhibidores de la interacción de menina-mll
KR20260099138A (ko) * 2023-10-20 2026-06-26 얀센 파마슈티카 엔브이 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법
WO2025188611A1 (en) * 2024-03-04 2025-09-12 Dana-Farber Cancer Institute, Inc. Chemical matters for targeting leukemic complex proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752639B2 (en) * 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
ES2831084T3 (es) * 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
AU2019337547A1 (en) * 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー,インク. メニン阻害剤を用いた血液悪性腫瘍の処置
WO2020142557A1 (en) * 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
IL297039A (en) * 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
JP7891524B2 (ja) * 2021-08-11 2026-07-16 バイオメア フュージョン,インコーポレイテッド 真性糖尿病に対するメニン-mll相互作用の共有結合性阻害剤

Also Published As

Publication number Publication date
EP4522174A1 (en) 2025-03-19
MX2024013787A (es) 2025-02-10
AU2023269033A1 (en) 2024-11-21
CN119403557A (zh) 2025-02-07
CA3252288A1 (en) 2023-11-16
JP2025516558A (ja) 2025-05-30
EP4522174A4 (en) 2026-05-20
US20250295661A1 (en) 2025-09-25
WO2023220098A1 (en) 2023-11-16
IL316829A (en) 2025-01-01
KR20250020447A (ko) 2025-02-11
CN120531737A (zh) 2025-08-26

Similar Documents

Publication Publication Date Title
CN120531737A (zh) 用于治疗癌症的menin-mll抑制剂
EP4149455A1 (en) Atr inhibitors for the treatment of cancer
CN117205312A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
JP7579781B2 (ja) Cdc7阻害剤を含む癌の治療方法
BR112021005518A2 (pt) métodos para tratar distúrbios mieloproliferativos
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
KR20200126388A (ko) Chk1 저해제를 포함하는 암의 치료 방법
JP2022518235A (ja) 進行期固形腫瘍がんの治療用rna
US20130316998A1 (en) Method for treating pancreatic cancer
KR20230087445A (ko) Aml의 치료 요법 및 rara 작용제, 저메틸화제, 및 bcl-2 억제제의 용도
CN113730572A (zh) 含有抗egfr抗体或其片段的联合用药物
US20240091183A1 (en) Treatment regimens with fixed doses of tamibarotene
US20190216923A1 (en) Methods and combination therapy to treat cancer
EP4604952A1 (en) Treatment of cancers having mutations in wnt pathway tumour suppressors
US20200368205A1 (en) Methods and combination therapy to treat cancer
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
Kalakonda et al. Selinexor in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): A Single-Arm Multinational Phase 2 Trial
Zhou et al. The N-butyl isothiocyanate inhibited breast cancer by suppressing MIF-CD74 interaction
HK40126790A (en) Treatment of cancers having mutations in wnt pathway tumour suppressors
AU2024294949A1 (en) Treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent
HK40105136A (en) Combinations of cabozantinib and atezolizumab to treat cancer
CN118201617A (zh) 包含pi3k及dna-pk双重抑制剂的外周t细胞淋巴瘤的预防或治疗用组合物
CN109939094A (zh) 用于治疗胰腺癌的治疗性组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination